{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:49:26Z","timestamp":1790394566419,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Given the common use of weight-inducing (WI) medications, it is crucial to understand the potential association of these medications with the effectiveness of obesity treatments.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the association between tirzepatide and weight reduction among participants with overweight or obesity who initiated WI medications during the SURMOUNT-1, -3, and -4 trials.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This post hoc analysis of the phase 3 randomized clinical trials SURMOUNT-1 (December 4, 2019, to April 1, 2022), SURMOUNT-3 (March 29, 2021, to May 12, 2023), and SURMOUNT-4 (March 29, 2021, to May 18, 2023) assessed the association between tirzepatide and weight reduction among participants taking concomitant WI medications. Randomized participants (lead-in and randomized treatment period data) who started taking 1 or more WI medications for 3 or more months (\u22651 week for oral corticosteroids) during the trial were included in the analysis. Statistical analysis was performed from July to December 2025 in the modified intent-to-treat population.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n WI medication use was summarized for all treatment arms from weeks 0 to 72 (SURMOUNT-1 and SURMOUNT-3) or weeks 0 to 88 (SURMOUNT-4). A mixed model of repeated measures was used to assess percentage change in weight from week 0 to week 72 or week 88 in the efficacy analysis sets (excluding off-treatment data), with 1 or more postbaseline weight measures.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This post hoc analysis comprised the WI medication subgroups of SURMOUNT-1 participants (N\u2009=\u2009442; mean [SD] age, 48.0 [12.5] years; 325 women [73.5%]; mean [SD] body weight, 105.9 [22.4] kg), SURMOUNT-3 participants (N\u2009=\u2009100; mean [SD] age, 49.5 [12.0] years; 75 women [75.0%]; mean [SD] body weight, 102.7 [23.5] kg), and SURMOUNT-4 participants (N\u2009=\u2009134; mean [SD] age, 51.8 [11.9] years; 91 women [67.9%]; mean [SD] body weight, 111.8 [23.7] kg). Approximately one-fifth of participants used 1 or more WI medications (SURMOUNT-1, 17.4% [442 of 2539]; SURMOUNT-3, 17.3% [100 of 579]; and SURMOUNT-4, 20.0% [134 of 670]). Among them, 72.9% in SURMOUNT-1 (322 of 442), 68.0% in SURMOUNT-3 (68 of 100), and 64.9% in SURMOUNT-4 (87 of 134) were taking 1 nonsteroid WI medication, with 2.0% in SURMOUNT-1 (9 of 442), 3.0% in SURMOUNT-3 (3 of 100), and 2.2% in SURMOUNT-4 (3 of 134) using 3 or more medications. The mean (SD) duration of treatment with nonsteroid WI medications was 50.9 (28.8) weeks in SURMOUNT-1, 50.9 (29.3) weeks in SURMOUNT-3, and 58.1 (34.9) weeks in SURMOUNT-4. The mean percentage weight change compared with placebo from randomization to 72 weeks for those treated with tirzepatide and using WI medication was \u221213.3% (95% CI, \u221216.0% to \u221210.7%) for 5 mg to \u221221.3% (95% CI, \u221223.9% to \u221218.7%) for 15 mg in SURMOUNT-1 and \u221226.1% (95% CI, \u221230.0% to \u221222.3%) for the maximum tolerated dose in SURMOUNT-3, and from randomization to 88 weeks, it was \u221218.6% (95% CI, \u221220.9% to \u221216.3%) for the maximum tolerated dose in SURMOUNT-4.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this post hoc analysis of 3 randomized clinical trials for participants taking at least 1 concomitant WI medication, tirzepatide treatment was associated with weight loss comparable with the primary study results. These findings suggest that people with overweight or obesity who require treatment with WI medications may be able to achieve clinically meaningful weight reduction with tirzepatide.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifiers:\n NCT04184622<\/jats:ext-link>\n ,\n NCT04657016<\/jats:ext-link>\n ,\n NCT04660643<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.3274","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:30:31Z","timestamp":1774539031000},"page":"e263274","source":"Crossref","is-referenced-by-count":4,"title":["Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications"],"prefix":"10.1001","volume":"9","author":[{"given":"Rodolfo J.","family":"Galindo","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Gudzune","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Look","sequence":"additional","affiliation":[{"name":"San Diego Sports Medicine and Family Health Center, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Benabbad","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuang","family":"Cao","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qier","family":"Meng","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Mojdami","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"10481","key":"zoi260132r1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"zoi260132r2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/ijerph14040435","article-title":"Economic burden of obesity: a systematic literature review.","volume":"14","author":"Tremmel","year":"2017","journal-title":"Int J Environ Res Public Health"},{"issue":"10431","key":"zoi260132r3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"issue":"21","key":"zoi260132r4","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association.","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"zoi260132r5","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"zoi260132r6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/oby.23068","article-title":"Pharmacogenomics of medication-induced weight gain and antiobesity medications.","volume":"29","author":"Singh","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"zoi260132r7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.gtc.2023.08.006","article-title":"Management of medication-induced weight gain.","volume":"52","author":"Barenbaum","year":"2023","journal-title":"Gastroenterol Clin North Am"},{"key":"zoi260132r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072686","article-title":"Effectiveness and safety of drugs for obesity.","volume":"384","author":"Henderson","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"zoi260132r11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi260132r12","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"zoi260132r13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"zoi260132r14","doi-asserted-by":"publisher","author":"Stevens","journal-title":"Int J Obes (Lond)","DOI":"10.1038\/sj.ijo.0803175"},{"issue":"2","key":"zoi260132r15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis.","volume":"100","author":"Domecq","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"zoi260132r16","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/oby.23869","article-title":"Use and continuity of weight-modifying medications among adults with diabetes and overweight\/obesity: US population study.","volume":"31","author":"Galindo","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"zoi260132r17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/DMSO.S171365","article-title":"Medications that cause weight gain and alternatives in Canada: a narrative review.","volume":"11","author":"Wharton","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"zoi260132r18","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/obr.12934","article-title":"Effects of antidepressant and antipsychotic use on weight gain: a systematic review.","volume":"20","author":"Alonso-Pedrero","year":"2019","journal-title":"Obes Rev"},{"key":"zoi260132r19","doi-asserted-by":"publisher","author":"Lopez","journal-title":"Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD008815.pub4"},{"issue":"1","key":"zoi260132r20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/13625187.2019.1709963","article-title":"Depo-medroxyprogesterone acetate, weight gain and amenorrhea among obese adolescent and adult women.","volume":"25","author":"Sims","year":"2020","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"zoi260132r21","doi-asserted-by":"publisher","author":"Gallo","journal-title":"Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD003987.pub5"},{"issue":"9922","key":"zoi260132r22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"9453","key":"zoi260132r23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer.","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"zoi260132r24","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients\u2014a systematic review and meta-analysis.","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"issue":"8","key":"zoi260132r25","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/art.39647","article-title":"Changes in body mass related to the initiation of disease-modifying therapies in rheumatoid arthritis.","volume":"68","author":"Baker","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"zoi260132r26","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/09546634.2021.1901845","article-title":"Effects of TNF inhibitors and an IL12\/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.","volume":"33","author":"Onsun","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"zoi260132r27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fphar.2020.00481","article-title":"Impact of TNF-a inhibitors on body weight and BMI: a systematic review and meta-analysis.","volume":"11","author":"Patsalos","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"zoi260132r28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae007","article-title":"Final 192-week efficacy and safety results of the ADVANCE trial, comparing 3 first-line antiretroviral regimens.","volume":"11","author":"Sokhela","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi260132r29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/oby.23299","article-title":"Use of prescription medications associated with weight gain among US adults, 1999-2018: a nationally representative survey.","volume":"30","author":"Hales","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"zoi260132r30","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12609","article-title":"Use of medications associated with weight change among participants in the All of Us research programme.","volume":"13","author":"Almazan","year":"2023","journal-title":"Clin Obes"},{"issue":"5","key":"zoi260132r31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/oby.22444","article-title":"Effect of obesogenic medications on weight-loss outcomes in a behavioral weight-management program.","volume":"27","author":"Desalermos","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"zoi260132r32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11920-023-01458-0","article-title":"Antipsychotic-induced weight gain in severe mental illness: risk factors and special considerations.","volume":"25","author":"Stogios","year":"2023","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"zoi260132r33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00125-024-06254-w","article-title":"Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.","volume":"68","author":"Khunti","year":"2025","journal-title":"Diabetologia"},{"issue":"5","key":"zoi260132r34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/osp4.686","article-title":"Health care providers\u2019 attitudes and counseling behaviors related to obesity.","volume":"9","author":"Smith","year":"2023","journal-title":"Obes Sci Pract"},{"issue":"1","key":"zoi260132r35","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12347","article-title":"Clinical encounters about obesity: systematic review of patients\u2019 perspectives.","volume":"10","author":"Ananthakumar","year":"2020","journal-title":"Clin Obes"},{"issue":"1","key":"zoi260132r36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1475-2891-12-44","article-title":"Clinician uptake of obesity-related drug information: a qualitative assessment using continuing medical education activities.","volume":"12","author":"Kohlstadt","year":"2013","journal-title":"Nutr J"},{"issue":"4","key":"zoi260132r37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2337\/cd22-0100","article-title":"Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study.","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin Diabetes"},{"issue":"12","key":"zoi260132r38","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/oby.2010.176","article-title":"Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey.","volume":"18","author":"Ratliff","year":"2010","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"zoi260132r39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13679-024-00598-5","article-title":"Antidepressants and weight gain: an update on the evidence and clinical implications.","volume":"14","author":"Moss","year":"2025","journal-title":"Curr Obes Rep"},{"issue":"20","key":"zoi260132r40","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi260132r9"},{"key":"zoi260132r10"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846962\/galindo_2026_oi_260132_1773945498.77825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:30:32Z","timestamp":1774539032000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846962"}},"subtitle":["Post Hoc Analysis of Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.3274","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}